EXPERIENCE

Christopher’s notable transactions include representing:

• Funds managed by affiliates of Apollo Global Management in:
  • its approximately $1.5 billion acquisition of Bridge Investment Group Holdings
  • their ¥311 billion investment (approximately $2.05 billion) to acquire a majority stake in Panasonic Automotive Systems Co. from Panasonic Holdings Corporation
• The Special Committee of Avangrid, a U.S. subsidiary of Iberdrola, in the $2.6 billion acquisition of the company’s remaining shares by Iberdrola
• Casey’s General Stores in its $1.145 billion acquisition of Fikes Wholesale
• Crown Castle in its successful proxy fight against Boots Capital
• General Mills in its $1.45 billion acquisition of Whitebridge Pet Brands’ North American premium Cat feeding and Pet treating business from NXMH
• IBM in its $6.4 billion acquisition of HashiCorp
• Restaurant Brands International in its $1 billion acquisition of Carrols Restaurant Group
• Rodina Capital in its acquisition of Rubicon Technologies’ fleet technology business unit and convertible preferred equity
• Sandvine in its in and out-of-court restructurings, including in its chapter 15 proceedings in the United States
• TPG Capital in its investment in G&A Partners

Prior to Paul, Weiss, Christopher’s experience includes advising:

• Altra Industrial Motion in its $5 billion sale to Regal Rexnord
• Amazon in its $8.45 billion acquisition of MGM
• British American Tobacco in its $97 billion merger with Reynolds American
• FS Investments in its combination with Portfolio Advisors, creating a $75 billion alternative investment firm
• Global Blood Therapeutics in its $5.4 billion sale to Pfizer
• IBM in multiple transactions, including the sale of its healthcare and data analytics assets, part of the Watson Health business, to Francisco Partners
• Mylan in its $50 billion combination with Upjohn, a division of Pfizer, to form Viatris
• Newcrest in its $28.8 billion acquisition by Newmont
• Pinnacle Foods in its $10.9 billion acquisition by Conagra Brands
• Viatris in its divestitures totaling $6.94 billion in value, including the $3.335 billion combination of its biosimilars portfolio with Biocon Biologics and the pending divestitures of its Over the Counter, Women’s Healthcare and Active Pharmaceutical Ingredients businesses